Mineralys Therapeutics Statistics Share Statistics Mineralys Therapeutics has 65.18M
shares outstanding. The number of shares has increased by 31.07%
in one year.
Shares Outstanding 65.18M Shares Change (YoY) 31.07% Shares Change (QoQ) 3.81% Owned by Institutions (%) 99.99% Shares Floating 40.71M Failed to Deliver (FTD) Shares 215 FTD / Avg. Volume 0.03%
Short Selling Information The latest short interest is 7.87M, so 12.07% of the outstanding
shares have been sold short.
Short Interest 7.87M Short % of Shares Out 12.07% Short % of Float 15.95% Short Ratio (days to cover) 14.08
Valuation Ratios The PE ratio is -3.36 and the forward
PE ratio is -4.15.
Mineralys Therapeutics's PEG ratio is
-0.04.
PE Ratio -3.36 Forward PE -4.15 PS Ratio 0 Forward PS 109.1 PB Ratio 3.12 P/FCF Ratio -3.59 PEG Ratio -0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Mineralys Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 14.02,
with a Debt / Equity ratio of 0.
Current Ratio 14.02 Quick Ratio 14.02 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-3.49M Employee Count 51 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 16.4% in the
last 52 weeks. The beta is -0.3, so Mineralys Therapeutics's
price volatility has been lower than the market average.
Beta -0.3 52-Week Price Change 16.4% 50-Day Moving Average 14.31 200-Day Moving Average 13.13 Relative Strength Index (RSI) 41.37 Average Volume (20 Days) 795,437
Income Statement
Revenue n/a Gross Profit n/a Operating Income -192.4M Net Income -177.81M EBITDA -177.77M EBIT -177.81M Earnings Per Share (EPS) -3.66
Full Income Statement Balance Sheet The company has 114.09M in cash and 0 in
debt, giving a net cash position of 114.09M.
Cash & Cash Equivalents 114.09M Total Debt n/a Net Cash n/a Retained Earnings -302.52M Total Assets 354.94M Working Capital 341.12M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -166.31M
and capital expenditures -96K, giving a free cash flow of -166.41M.
Operating Cash Flow -166.31M Capital Expenditures -96K Free Cash Flow -166.41M FCF Per Share -3.43
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
